Journal
JOURNAL OF NEUROLOGY
Volume 250, Issue -, Pages 31-34Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s00415-003-1106-y
Keywords
Parkinson therapy; L-DOPA therapy; neuroprotection; catechol-O-methyltransferase (COMT) inhibitors; tolcapone; selegiline
Categories
Ask authors/readers for more resources
An essential element of pharmaceutical development, defined as the period between the discovery of a new agent and its market release, is provided by the cc preclinical studies. They consist of the in vitro and in vivo studies performed before examination of the agent in human subjects. Regulatory authorities prescribe specific requirements regarding the nature and number of preclinical studies. In the present paper, we discuss the relevance of these studies for the treatment of Parkinson's disease (PD) on the basis of three examples: the L-DOPA (L-3,4-dihydroxyphenylalanine, levodopa) story; the development of selegiline as a palliative and neuroprotective drug; and the safety concerns regarding tolcapone, an inhibitor of central and peripheral catechol-O-methyltransferase (COMT).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available